• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Understand Current Epidemiological Trends in Gynecological Cancer and Ongoing Treatment Controversies Inside 2006 Report Gynecological Cancers - Niche Opportunities in Advanced Disease

Posted on: Friday, 26 January 2007, 12:00 CST

Research and Markets (http://www.researchandmarkets.com/reports/c49312) has announced the addition of Stakeholder Opinions: Gynecological Cancers - Niche Opportunities in Advanced Disease to their offering.

Cases of endometrial cancer are set to rise in developed countries due to an increase in risk factors such as obesity.

In contrast, while incidence of cervical cancer is set to decrease in developed countries following the implementation of anti-HPV immunization with Merck & Co's Gardasil and GlaxoSmithKline's Cervarix, it will remain a major cause of cancer-related death in the developing world.

Scope of this title:

Current diagnosis and treatment of endometrial, cervical, vaginal and vulvar cancer, including treatment regimens by stage of disease

Issues and unmet needs in current treatment, screening and potential anti-HPV vaccination programs

Examination of pipeline activity and potential future opportunities for drug developers

Stakeholder opinions and interview transcripts based on qualitative interviews with five opinion leaders from the US and Europe

Highlights of this title:

The advent of anti-HPV vaccines capable of preventing cervical cancer, Merck & Co's Gardasil and GlaxoSmithKline's Cervarix, represent a major breakthrough, capable of significantly reducing the burden of disease. However, maximal impact will depend on the ease by which cash-strapped developing countries are able to gain access to these vaccines.

Despite being the most common of the gynecological malignancies, drug development for endometrial cancer is minimal. Given the high rate of early diagnosis and cure, the development of systemic therapies for metastatic disease has not been prioritized. This relatively inactive pipeline may become more of an issue as disease incidence increases.

While ample Phase I/II clinical trial data has been reported for the gynecological malignancies, only a small number of Phase III studies have been completed to corroborate earlier results. To fully define treatment strategies and provide solid evidence for clinical decision making, more large-scale, randomized clinical trials are necessary.

Reasons to order your copy:

Identify the limitations of current therapy for gynecological cancer and the potential of future therapy

Understand current epidemiological trends in gynecological cancer and ongoing treatment controversies

Assess the opportunities for innovative targeted therapies in gynecological cancer, particularly in metastatic disease

Chapter Outline:

Chapter 1. Executive summary

Chapter 2. Disease overview

Chapter 3. Current treatment options

Chapter 4. Current treatment regimens and controversies

Chapter 5. Unmet needs

Chapter 6. Pipeline analysis

Chapter 7. Key opinion leader interview transcripts

APPENDIX

Bibliography

List of Tables

List of Figures

For more information visit http://www.researchandmarkets.com/reports/c49312

Source: Datamonitor

Source: Business Wire

More News in this Category